A Phase 2 interventional study of VX-548 and HB/APAP in Acute Pain, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 7 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-12-27.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing suzetrigine in Acute Pain — 3 open to participants now, 3 under way, none of them phase 3. suzetrigine · Acute Pain.
Among the 10 studies testing suzetrigine in Acute Pain, this one is the 3rd largest by enrollment, is one of 2 that started in 2021, is one of 2 in phase 2, and was the 2nd registered.
1,075 studies on the registry are indexed under Acute Pain; 168 are open to participants now.
Browse Acute Pain studies →3 of the 10 studies testing suzetrigine in Acute Pain are open now, in 1 country. Recruiting first, the newest first:
University of Minnesota · Sites in United States
Ages 18+
Stanford University · Sites in United States
Ages 18+
Soheil Ashkani Esfahani
Ages 18–75
By country, each count listing its studies:
suzetrigine: first FDA approval 2025 (JOURNAVX). What it is approved for, and how studies give it, is on its page →
Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 2 started in 2021.
This study's enrollment of 303 is above the median of 86 across 903 interventional studies indexed under Acute Pain.
Median enrollment 165 across the 10 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 10 have an industry lead sponsor. The 5 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
10 studies in Acute Pain by Vertex Pharmaceuticals Incorporated: none open now, none under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 10 studies in Acute Pain by Vertex Pharmaceuticals Incorporated, this one is the 4th largest by enrollment, is one of 2 that started in 2021, is one of 5 in phase 2, and was the 4th registered.
Vertex Pharmaceuticals Incorporated’s Acute Pain studies by the year they started, since 2017.
2 of the studies testing suzetrigine in Acute Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07821931Stanford UniversitySuzetrigine in Tonsillectomy for Opioid-sparing Pain Management | 2027-06 |
| NCT07795827Soheil Ashkani EsfahaniSuzetrigine for Postoperative Pain After Total Ankle Replacement | 2027-10-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing suzetrigine in Acute Pain, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 10 in Acute Pain:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of VX-548 doses in treating acute pain after an abdominoplasty.
Key Inclusion Criteria:
Before Surgery:
After Surgery:
Key Exclusion Criteria
Before Surgery:
After Surgery:
Other protocol defined Inclusion/Exclusion criteria may apply.
Participants received placebo matched to VX-548 and Hydrocodone bitartrate/ acetaminophen (HB/APAP) for 2 days.
Drug: Placebo (matched to VX-548) · Drug: Placebo (matched to HB/APAP)
Participants received HB 5 mg / APAP 325 milligrams (mg) every 6 hours (q6h) for 2 days.
Drug: HB/APAP
Participants received VX-548 60 mg as first dose, followed by VX-548 30 mg every 12 hours (q12h) for 2 days.
Drug: VX-548
Participants received VX-548 100 mg as first dose, followed by VX-548 50 mg q12h for 2 days.
Drug: VX-548
Tablets for oral administration.
Also known as: Suzetrigine
Drug pages: Hydrocodone · Acetaminophen
Capsules for oral administration.
Placebo matched to VX-548 for oral administration.
Placebo matched to HB/APAP for oral administration.
Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) at Rest 0 to 48 Hours (SPIDr0-48) After the First Dose of Study Drug
SPID was calculated as the sum of the product of time (in hours) elapsed since previous measurements and pain intensity difference. Pain intensity difference was calculated by subtracting the pain intensity score at given post-dose time points from the baseline pain intensity scores (using pain rating score range: 0= no pain to 10= worst possible pain). SPIDr0-48 was calculated from 0 to 48 hours and the score range was -480 (worst score) to 480 (best score).
Time frame: 0 to 48 Hours After First Dose of Study Drug
Time-weighted SPID as Recorded on an NPRS at Rest 0 to 24 Hours (SPIDr0-24) After the First Dose of Study Drug
SPID was calculated as the sum of the product of time (in hours) elapsed since previous measurements and pain intensity difference. Pain intensity difference was calculated by subtracting the pain intensity score at given post-dose time points from the baseline pain intensity scores (using pain rating score range: 0= no pain to 10= worst possible pain). SPIDr0-24 was calculated from 0 to 24 hours and the score range was -240 (worst score) to 240 (best score).
Time frame: 0 to 24 Hours After First Dose of Study Drug
Percentage of Participants With at Least 30 Percent (%),Reduction in NPRS (at Rest) at 48 Hours After the First Dose of Study Drug
Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain. The percentage of participants with at least 30% reduction from baseline in NPRS at 48 hours after the first dose of VX-548 or placebo were reported.
Time frame: From Baseline At 48 Hours After First Dose of Study Drug
Percentage of Participants With at Least 50% Reduction in NPRS (at Rest) at 48 Hours After the First Dose of Study Drug
Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0=no pain and 10=worst imaginable pain. The percentage of participants with at least 50% reduction from baseline in NPRS at 48 hours after the first dose of VX-548, HB/APAP, or placebo were reported.
Time frame: From Baseline At 48 Hours After First Dose of Study Drug
Percentage of Participants With at Least 70% Reduction in NPRS (at Rest) at 48 Hours After the First Dose of Study Drug
Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain. The percentage of participants with at least 70% reduction from baseline in NPRS at 48 hours after the first dose of VX-548,HB/APAP or placebo were reported.
Time frame: From Baseline at 48 Hours After First Dose of Study Drug
Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: Day 1 up to Day 16
| Milestone | Placebo | HB/APAP | VX-548: Low Dose | VX-548: High Dose |
|---|---|---|---|---|
| Started | 77 | 76 | 74 | 76 |
| Completed | 75 | 70 | 70 | 72 |
| Not completed | 2 | 6 | 4 | 4 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal of consent (not due to ae) | 0 | 2 | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 4 | 3 | 3 |
| Withdrew: Other | 0 | 0 | 0 | 1 |
SPID was calculated as the sum of the product of time (in hours) elapsed since previous measurements and pain intensity difference. Pain intensity difference was calculated by subtracting the pain intensity score at given post-dose time points from the baseline pain intensity scores (using pain rating score range: 0= no pain to 10= worst possible pain). SPIDr0-48 was calculated from 0 to 48 hours and the score range was -480 (worst score) to 480 (best score).
| units on a scale | Placebo | HB/APAP | VX-548: Low Dose | VX-548: High Dose |
|---|---|---|---|---|
| Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) at Rest 0 to 48 Hours (SPIDr0-48) After the First Dose of Study Drug | 72.73 ± 10.23 | 85.20 ± 10.30 | 95.11 ± 10.44 | 110.53 ± 10.30 |
SPID was calculated as the sum of the product of time (in hours) elapsed since previous measurements and pain intensity difference. Pain intensity difference was calculated by subtracting the pain intensity score at given post-dose time points from the baseline pain intensity scores (using pain rating score range: 0= no pain to 10= worst possible pain). SPIDr0-24 was calculated from 0 to 24 hours and the score range was -240 (worst score) to 240 (best score).
| units on a scale | Placebo | HB/APAP | VX-548: Low Dose | VX-548: High Dose |
|---|---|---|---|---|
| Time-weighted SPID as Recorded on an NPRS at Rest 0 to 24 Hours (SPIDr0-24) After the First Dose of Study Drug | 25.96 ± 4.70 | 29.98 ± 4.73 | 37.65 ± 4.79 | 45.54 ± 4.73 |
Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain. The percentage of participants with at least 30% reduction from baseline in NPRS at 48 hours after the first dose of VX-548 or placebo were reported.
| percentage of participants | Placebo | HB/APAP | VX-548: Low Dose | VX-548: High Dose |
|---|---|---|---|---|
| Percentage of Participants With at Least 30 Percent (%),Reduction in NPRS (at Rest) at 48 Hours After the First Dose of Study Drug | 48.1 | 53.9 | 59.5 | 60.5 |
Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0=no pain and 10=worst imaginable pain. The percentage of participants with at least 50% reduction from baseline in NPRS at 48 hours after the first dose of VX-548, HB/APAP, or placebo were reported.
| percentage of participants | Placebo | HB/APAP | VX-548: Low Dose | VX-548: High Dose |
|---|---|---|---|---|
| Percentage of Participants With at Least 50% Reduction in NPRS (at Rest) at 48 Hours After the First Dose of Study Drug | 33.8 | 42.1 | 43.2 | 44.7 |
Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain. The percentage of participants with at least 70% reduction from baseline in NPRS at 48 hours after the first dose of VX-548,HB/APAP or placebo were reported.
| percentage of participants | Placebo | HB/APAP | VX-548: Low Dose | VX-548: High Dose |
|---|---|---|---|---|
| Percentage of Participants With at Least 70% Reduction in NPRS (at Rest) at 48 Hours After the First Dose of Study Drug | 14.3 | 23.7 | 18.9 | 25.0 |
| Participants | Placebo | HB/APAP | VX-548: Low Dose | VX-548: High Dose |
|---|---|---|---|---|
| Participants with TEAEs | 54 | 46 | 45 | 42 |
| Participants with SAEs | 1 | 1 | 1 | 0 |
Collected over Day 1 up to Day 16. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/77 (0%) | 1/77 (1.3%) | 40/77 (51.9%) |
| HB/APAP | 0/76 (0%) | 1/76 (1.3%) | 37/76 (48.7%) |
| VX-548 Low Dose | 0/74 (0%) | 1/74 (1.4%) | 37/74 (50%) |
| VX-548 High Dose | 0/76 (0%) | 0/76 (0%) | 33/76 (43.4%) |
| Event | Placebo | HB/APAP | VX-548 Low Dose | VX-548 High Dose |
|---|---|---|---|---|
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/77 | 0/76 | 1/74 | 0/76 |
| Laryngeal stenosisRespiratory, thoracic and mediastinal disorders | 0/77 | 1/76 | 0/74 | 0/76 |
| Incision site cellulitisInfections and infestations | 1/77 | 0/76 | 0/74 | 0/76 |
| SepsisInfections and infestations | 1/77 | 0/76 | 0/74 | 0/76 |
| Event | Placebo | HB/APAP | VX-548 Low Dose | VX-548 High Dose |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 28/77 | 23/76 | 22/74 | 14/76 |
| DizzinessNervous system disorders | 14/77 | 8/76 | 11/74 | 6/76 |
| HeadacheNervous system disorders | 5/77 | 5/76 | 6/74 | 11/76 |
| ConstipationGastrointestinal disorders | 4/77 | 9/76 | 7/74 | 7/76 |
| VomitingGastrointestinal disorders | 5/77 | 8/76 | 1/74 | 2/76 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 2/77 | 2/76 | 4/74 | 1/76 |
| HypotensionVascular disorders | 3/77 | 3/76 | 4/74 | 1/76 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 4/77 | 1/76 | 2/74 | 2/76 |
All randomized participants who had received at least one dose of the study drug during the treatment period were included in the baseline analysis.
| Age, Continuous(years) | Placebo | HB/APAP | VX-548: Low Dose | VX-548: High Dose | Total |
|---|---|---|---|---|---|
| Mean | 42.6 ± 9.5 | 45.4 ± 10.7 | 41.5 ± 9.2 | 43.1 ± 9.7 | 43.2 ± 9.9 |
| Sex: Female, Male(Participants) | Placebo | HB/APAP | VX-548: Low Dose | VX-548: High Dose | Total |
|---|---|---|---|---|---|
| Female | 76 | 73 | 74 | 75 | 298 |
| Male | 1 | 3 | 0 | 1 | 5 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | HB/APAP | VX-548: Low Dose | VX-548: High Dose | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 14 | 20 | 21 | 25 | 80 |
| Not Hispanic or Latino | 63 | 56 | 53 | 51 | 223 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | HB/APAP | VX-548: Low Dose | VX-548: High Dose | Total |
|---|---|---|---|---|---|
| White | 57 | 53 | 57 | 57 | 224 |
| Black or African American | 20 | 18 | 15 | 13 | 66 |
| American Indian or Alaska Native | 0 | 1 | 0 | 1 | 2 |
| Native Hawaiian or other Pacific Islander | 0 | 2 | 0 | 2 | 4 |
| Other | 0 | 2 | 1 | 1 | 4 |
| Multiracial | 0 | 0 | 1 | 2 | 3 |
| Pain Intensity at Baseline (at 0 hours) as Recorded on Numeric Pain Rating Scale (NPRS)(units on a scale) | Placebo | HB/APAP | VX-548: Low Dose | VX-548: High Dose | Total |
|---|---|---|---|---|---|
| Mean | 7.4 ± 1.6 | 7.3 ± 1.8 | 7.4 ± 1.8 | 7.2 ± 1.7 | 7.3 ± 1.7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
Ran from Aug 2021 to primary completion in Dec 2021, 3 months.
Results were first posted in Dec 2024, 3 years after primary completion. A results delay was requested in Dec 2022.
Of 40 phase 2 interventional studies under Acute Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's 3 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Suzetrigine
Vertex Pharmaceuticals Incorporated →